US EditionPublished • loading... • Updated
Indiana AG files state lawsuit against Eli Lilly over insulin prices
Indiana AG alleges Eli Lilly and others inflated insulin prices for a decade despite low costs, seeking remedies to reduce prices for nearly 700,000 diagnosed Hoosiers.
- On Monday, Indiana Attorney General Todd Rokita filed a lawsuit in Lake County accusing Eli Lilly of participating in a scheme that inflated insulin prices, building on prior legal actions.
- The complaint alleges coordinated deals with pharmacy benefit managers and secret rebates that inflated insulin sticker prices, with some products priced roughly $300 to $700 despite manufacturing costs estimated under $2.
- Seeking broader relief, Rokita pursues structural market changes, damages and penalties, and aims to add Indiana to ongoing multistate litigation to share evidence and any settlements.
- Officials say nearly 700,000 Indiana residents have been diagnosed with diabetes and could be affected by changes, while Eli Lilly claims a 70% price cut and a $35 monthly cap with under $15 average out-of-pocket in 2024.
- Indiana joins states including Texas, California, Minnesota and Michigan suing Eli Lilly, the first U.S. drugmaker valued at more than $1 trillion, whose growth partly stems from Mounjaro and past federal government collaboration on Medicare insulin pricing.
Insights by Ground AI
20 Articles
20 Articles
Coverage Details
Total News Sources20
Leaning Left4Leaning Right1Center12Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
L 23%
C 71%
Factuality
To view factuality data please Upgrade to Premium
